Predicting rapid cognitive decline in Alzheimer's disease patients using quantitative EEG markers and neuropsychological test scores

2016 ◽  
Author(s):  
Carmina Reyes-Coronel ◽  
Markus Waser ◽  
Heinrich Garn ◽  
Manfred Deistler ◽  
Peter Dal-Bianco ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Test Scores ◽  
Neuropsychological Test ◽  
Quantitative Eeg ◽  
Rapid Cognitive Decline

Risk Factors for Rapid Cognitive Decline in Alzheimer’s Disease

2017 ◽  
Vol 7 (5) ◽  
pp. 770-776
Author(s):  
Myung Chul Kim ◽  
Eun Hye Jeong ◽  
Hyun Keun Lee ◽  
Young Kyu Park
Keyword(s):  
Risk Factors ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Rapid Cognitive Decline

Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease

2017 ◽  
Vol 13 (5) ◽  
pp. 592-597 ◽  
Author(s):  
Jianping Jia ◽  
Serge Gauthier ◽  
Sarah Pallotta ◽  
Yong Ji ◽  
Wenshi Wei ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Rapid Cognitive Decline

scholarly journals Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing

2011 ◽  
Vol 24 (2) ◽  
pp. 197-204 ◽  
Author(s):  
Alessandro Sona ◽  
Ping Zhang ◽  
David Ames ◽  
Ashley I. Bush ◽  
Nicola T. Lautenschlager ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Rating Scale ◽  
Cognitive Status ◽  
Imaging Biomarkers ◽  
Clinical Dementia Rating ◽  
Factors Associated ◽  
Biological Variables ◽  
Rapid Cognitive Decline

ABSTRACTBackground: The AIBL study, which commenced in November 2006, is a two-center prospective study of a cohort of 1112 volunteers aged 60+. The cohort includes 211 patients meeting NINCDS-ADRDA criteria for Alzheimer's disease (AD) (180 probable and 31 possible). We aimed to identify factors associated with rapid cognitive decline over 18 months in this cohort of AD patients.Methods: We defined rapid cognitive decline as a drop of 6 points or more on the Mini-Mental State Examination (MMSE) between baseline and 18-month follow-up. Analyses were also conducted with a threshold of 4, 5, 7 and 8 points, as well as with and without subjects who had died or were too severely affected to be interviewed at 18 months and after, both including and excluding subjects whose AD diagnosis was “possible” AD. We sought correlations between rapid cognitive decline and demographic, clinical and biological variables.Results: Of the 211 AD patients recruited at baseline, we had available data for 156 (73.9%) patients at 18 months. Fifty-one patients were considered rapid cognitive decliners (32.7%). A higher Clinical Dementia Rating scale (CDR) and higher CDR “sum of boxes” score at baseline were the major predictors of rapid cognitive decline in this population. Furthermore, using logistic regression model analysis, patients treated with a cholinesterase inhibitor (CheI) had a higher risk of being rapid cognitive decliners, as did males and those of younger age.Conclusions: Almost one third of patients satisfying established research criteria for AD experienced rapid cognitive decline. Worse baseline functional and cognitive status and treatment with a CheI were the major factors associated with rapid cognitive decline over 18 months in this population.

scholarly journals The Pathology of Rapid Cognitive Decline in Clinically Diagnosed Alzheimer’s Disease

2019 ◽  
Vol 70 (4) ◽  
pp. 983-993 ◽  
Author(s):  
Christin Nance ◽  
Aaron Ritter ◽  
Justin B. Miller ◽  
Brittany Lapin ◽  
Sarah J. Banks
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Rapid Cognitive Decline

O2-04-07: Most rapid cognitive decline in APOE4 negative Alzheimer's disease with early onset

2009 ◽  
Vol 5 (4S_Part_4) ◽  
pp. P111-P112
Author(s):  
Wiesje M. van der Flier ◽  
Annelies E. van der Vlies ◽  
Esther L. Koedam ◽  
Yolande A.L. Pijnenburg ◽  
Jos W.R. Twisk ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Early Onset ◽  
Rapid Cognitive Decline

scholarly journals Trajectories of cognitive decline in Alzheimer's disease

2009 ◽  
Vol 22 (2) ◽  
pp. 281-290 ◽  
Author(s):  
Patricia A. Wilkosz ◽  
Howard J. Seltman ◽  
Bernie Devlin ◽  
Elise A. Weamer ◽  
Oscar L. Lopez ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Complex Disease ◽  
Latent Class ◽  
Rating Scale ◽  
Late Onset ◽  
Psychotic Symptoms ◽  
Concomitant Variables ◽  
Rapid Cognitive Decline

ABSTRACTBackground: Late-onset Alzheimer disease (LOAD) is a clinically heterogeneous complex disease defined by progressively disabling cognitive impairment. Psychotic symptoms which affect approximately one-half of LOAD subjects have been associated with more rapid cognitive decline. However, the variety of cognitive trajectories in LOAD, and their correlates, have not been well defined. We therefore used latent class modeling to characterize trajectories of cognitive and behavioral decline in a cohort of AD subjects.Methods: 201 Caucasian subjects with possible or probable Alzheimer's disease (AD) were evaluated for cognitive and psychotic symptoms at regular intervals for up to 13.5 years. Cognitive symptoms were evaluated serially with the Mini-mental State Examination (MMSE), and psychotic symptoms were rated using the CERAD behavioral rating scale (CBRS). Analyses undertaken were latent class mixture models of quadratic trajectories including a random intercept with initial MMSE score, age, gender, education, and APOE ϵ4 count modeled as concomitant variables. In a secondary analysis, psychosis status was also included.Results: AD subjects showed six trajectories with significantly different courses and rates of cognitive decline. The concomitant variables included in the best latent class trajectory model were initial MMSE and age. Greater burden of psychotic symptoms increased the probability of following a trajectory of more rapid cognitive decline in all age and initial MMSE groups. APOE ϵ4 was not associated with any trajectory.Conclusion: Trajectory modeling of longitudinal cognitive and behavioral data may provide enhanced resolution of phenotypic variation in AD.

scholarly journals Factors Affecting Rapid Cognitive Decline in Patients with Alzheimer’s Disease: A Longitudinal Follow-Up Study

2021 ◽  
Vol 18 (16) ◽  
pp. 8576
Author(s):  
Chih-Chuan Pan ◽  
Che-Sheng Chu ◽  
Chien-Liang Chen ◽  
Yao-Chung Chuang ◽  
Nai-Ching Chen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Protective Factor ◽  
Proportional Hazards ◽  
Acetylcholinesterase Inhibitors ◽  
Cox Proportional Hazards ◽  
Research Database ◽  
Clinical Dementia Rating ◽  
Rapid Cognitive Decline

We investigated the preventive and risk factors of rapid cognitive decline in patients with Alzheimer’s disease (AD). Using the Chang Gung Research Database (CGRD), we enrolled patients with AD aged over 65 years between 1 January 2001 and 30 May 2019, and followed up for at least two years. Rapid cognitive decline was defined by a Mini-Mental State Examination (MMSE) score decline of ≥4 in 2 years. A longer prescription of acetylcholinesterase inhibitors (AChEIs) was defined as 22 months based on the median treatment duration of the cohorts. The Cox proportional hazards regression model adjusted for age, sex, medication, and physical comorbidities was used to examine the candidate risk and protective factors. We analyzed data from 3846 patients with AD (1503 men, 2343 women) with a mean age and percentage of females of 77.8 ± 6.2 years and 60.9%, respectively. The mean duration of patients with AD receiving AChEIs was 658.7 ± 21.9 days. In general, 310 patients with AD showed a rapid cognitive decline, accounting for 8.1%. Treatment of a consecutive AChEI prescription for >22 months in patients with AD was a protective factor against rapid cognitive decline (adjusted hazard ratio (aHR) = 0.41, 95% confidence interval (CI) = 0.33–0.52, p < 0.001). Patients with AD aged >85 years (aHR = 0.53, 95% CI = 0.36–0.79, p < 0.01) and aged 75–85 years (aHR = 0.73, 95% CI = 0.57–0.93, p < 0.05) had a significantly lower risk of rapid cognitive decline than those aged 65–75 years. Additionally, patients with mild and moderate AD (clinical dementia rating (CDR = 1, aHR = 1.61, 95% CI = 1.26–2.07, p < 0.001; CDR = 2, aHR = 2.64, 95% CI = 1.90–3.65, p < 0.001) were more likely to have rapid cognitive decline than those with early AD (CDR = 0.5). Sex, medication with different types of AChEIs, and physical comorbidities were not associated with rapid cognitive decline. These findings indicate that it is important to maintain longer consecutive AChEI prescriptions in patients with AD to prevent cognitive decline.

scholarly journals Diagnosis of Alzheimer’s disease patients with rapid cognitive decline in clinical practice: Interest of the Deco questionnaire

2011 ◽  
Vol 15 (5) ◽  
pp. 361-366 ◽  
Author(s):  
Laure Carcaillon ◽  
G. Berrutp ◽  
F. Sellalm ◽  
J. F. Dartigues ◽  
S. Gillette ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Practice ◽  
Cognitive Decline ◽  
Rapid Cognitive Decline
Sign in / Sign up

Export Citation Format

Share Document